Pacific Biosciences of California Receivables

Pacific Biosciences of California posts a receivables of $29M as of March 2026. That compares with $32M in the prior-year period — down 7.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Pacific Biosciences of California's receivables was $32M. The latest reading is $29M — a 7.3% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Pacific Biosciences of California's financial statement story. At $29M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PACB's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Pacific Biosciences of California's other metric pages and overview cover the third.

Judging Pacific Biosciences of California against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $29M here, then scan peer and history charts to see if the gap is persistent.